PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search > PAD Profile : Molnupiravir - Covid-19

PAD Profile : Molnupiravir - Covid-19

Keywords :
Covid 19, Coronavirus, antivirals
Brand Names Include :
Lagevrio

Traffic Light Status

Status 1 of 2.

Status :
See narrative
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Status 2 of 2.

Status :
See narrative
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

No indications returned.

Additional Documents

No additional documents returned.

Committee Recommendations

Date
Committee Name
Narrative
07 February 2022
Surrey Heartlands Medicines Optimisation Board (MOB)

DO NOT prescribe in primary care.

This drug is recommended in the treatment of COVID-19 ONLY in line with NHSE commissioning policies (links below) which include detail on eligibility and exclusion criteria for:

  • Non-hospitalised patients - Refer eligible patients from Surrey Heartlands and Frimley to the East Berkshire Primary Care Covid Medicine Delivery Unit.
  • Hospitalised patients – Hospital treatment of those with acute Covid-19 illness OR with hospital onset Covid-19
09 November 2021
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Do not prescribe.

It is anticipated that this drug will be part of a central, national distribution process.

Further details will follow.

Associated BNF Codes

No BNF codes returned.

This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More